Free Trial
NASDAQ:BIOA

BioAge Labs Q1 2026 Earnings Results & Report

BioAge Labs logo
$5.65 -0.22 (-3.75%)
Closing price 04:00 PM Eastern
Extended Trading
$5.70 +0.05 (+0.88%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioAge Labs beat analyst earnings expectations in its Q1 2026 results, released May 8, 2026. The company reported EPS of -$0.52 versus the -$0.71 consensus estimate, while revenue was $2.77 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

BioAge Labs EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.71
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

BioAge Labs Revenue Results

Actual Revenue
$2.77 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioAge Labs Q1 2026 Earnings FAQ

BioAge Labs (NASDAQ:BIOA) reported earnings of -$0.52 per share for Q1 2026, beating the consensus estimate of -$0.71. The report was announced on Friday, May 8, 2026.

BioAge Labs reported revenue of $2.77 million for Q1 2026.

BioAge Labs Earnings Headlines

BTIG Research Reaffirms Buy Rating for BioAge Labs (NASDAQ:BIOA)
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More BioAge Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAge Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAge Labs and other key companies, straight to your email.

About BioAge Labs

BioAge Labs (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment.

The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.

Founded in 2015, BioAge is headquartered in Richmond, California. Co-founder Kristen Fortney, Ph.D., serves as the company’s chief executive officer.

View BioAge Labs Profile